Efficacy and safety of the cladribine, idarubicin, and cytarabine regimen for treating acute myeloid leukemia: a systematic review and single-arm meta-analysis
DARU Journal of Pharmaceutical Sciences · 09.11.2026 · 35 (1)
DOI: 10.1007/s40199-026-00692-0 ↗Kurz gefasst
Metaanalyse in der Zeitschrift DARU Journal of Pharmaceutical Sciences, online erschienen am 09.11.2026. Verfasst von Yichen Xu und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Sciences and Materials Chemistry, College of Science & Technology Ningbo University, Ningbo, China. 2946326557@qq.com. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Cladribine, Cytarabine, Idarubicin. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
OBJECTIVES: This research sought to provide exploratory evidence regarding the efficacy and safety of the cladribine, idarubicin, and cytarabine (CIA) regimen for acute myeloid leukemia (AML). EVIDENCE ACQUISITION: PubMed, Cochrane Library, Web of Science, and Embase databases were retrieved up to September 9, 2025. Meta-analysis was implemented utilizing R (version 4.5.1). RESULTS: All efficacy endpoints were analyzed and reported separately by disease status. In newly diagnosed (ND) AML, pooled estimates were: complete remission (CR), 72.7% (95% confidence interval [CI]: 66.4%-79.0%); complete remission with incomplete hematologic recovery (CRi), 7.1% (95% CI: 3.7%-10.6%); overall response rate (ORR), 80.4% (95% CI: 76.8%-84.0%); 1-year overall survival (OS), 60.5% (95% CI: 53.5%-67.5%); and 2-year OS, 65.5% (95% CI: 33.4%-97.5%). For relapsed/refractory (R/R) AML, only CR could be quantitatively pooled (pooled estimate 37.1%, 95% CI: 7.5%-66.6%), albeit with limited statistical power. CRi, ORR, and OS were not pooled owing to insufficient studies; available data are described narratively. The pooled safety estimates were: rash/skin reaction 34.3% (95% CI: 0.0%-85.0%), severe infection in ND AML 59.5% (25.2%-93.8%), severe bleeding in ND AML 5.9% (2.8%-9.0%), and 28-day all-cause mortality 6.1% (1.1%-11.2%). CONCLUSIONS: Results indicate promising remission in ND AML, particularly low- to intermediate-risk cases. In contrast, efficacy is limited in R/R AML. Severe infections remain a major safety concern. Given the small number of studies and single-arm pooling, findings should be interpreted with caution. Future research should prioritize larger well-defined R/R AML cohorts, standardized CIA dosing regimens, and head-to-head randomized controlled trials against contemporary standard-of-care regimens (e.g., 7 + 3 plus gemtuzumab ozogamicin, CPX-351, and venetoclax-based combinations). Further exploration of CIA combined with molecular targeted agents (e.g., FLT3/IDH inhibitors) and standardized reporting of long-term endpoints including event-free survival and relapse-free survival are warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Life Sciences and Materials Chemistry, College of Science & Technology Ningbo University, Ningbo, China. 2946326557@qq.com.
- The Second Clinical Medical College, Wenzhou Medical University, Wenzhou, China.
Zitieren
APA
Xu, Y., Chen, S., & Zhang, R. (2026). Efficacy and safety of the cladribine, idarubicin, and cytarabine regimen for treating acute myeloid leukemia: a systematic review and single-arm meta-analysis. DARU Journal of Pharmaceutical Sciences, 35(1). https://doi.org/10.1007/s40199-026-00692-0
Vancouver
Xu Y, Chen S, Zhang R. Efficacy and safety of the cladribine, idarubicin, and cytarabine regimen for treating acute myeloid leukemia: a systematic review and single-arm meta-analysis. DARU Journal of Pharmaceutical Sciences. 2026;35(1). doi:10.1007/s40199-026-00692-0
BibTeX
@article{Xu2026,
author = {Xu, Yichen and Chen, Shuai and Zhang, Ruolin},
title = {Efficacy and safety of the cladribine, idarubicin, and cytarabine regimen for treating acute myeloid leukemia: a systematic review and single-arm meta-analysis},
journal = {DARU Journal of Pharmaceutical Sciences},
year = {2026},
volume = {35},
number = {1},
doi = {10.1007/s40199-026-00692-0}
}
EUVIMED